Literature DB >> 21685532

Polymorphisms of toll-like receptors and their pathways in viral hepatitis.

Rohit Sawhney1, Kumar Visvanathan.   

Abstract

Toll-like receptors (TLRs) are an important part of the innate immune response to a variety of pathogens including hepatic viral infections. Activation of TLRs stimulates a complex intracellular signalling cascade that results in production of proinflammatory cytokines and interferons important for antiviral responses as well as induction of the adaptive arm of the immune system. There is substantial evidence for an important role for TLRs and TLR-mediated signalling in the pathogenesis and outcomes of hepatitis B and C in particular, but it might also influence responses to other viral hepatitis infections. Several single nucleotide polymorphisms (SNPs) of TLRs, relevant adaptor molecules and cytokines mediated by TLR signalling have been described that alter innate immune responses and have been implicated in a variety of human diseases including viral and other infections. There is now significant evidence that a number of TLR SNPs can affect various clinical outcomes in Caucasian patients with chronic HCV. However, the role of these polymorphisms in acute and other chronic hepatitis infections, including HBV as well as in non-Caucasian populations, has not been elucidated. In addition, results for SNPs downstream of TLR activation, such as in relevant cytokines, are inconsistent and their influence requires further investigation to determine the clinical significance of genetic variations in these mediators.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21685532     DOI: 10.3851/IMP1820

Source DB:  PubMed          Journal:  Antivir Ther        ISSN: 1359-6535


  9 in total

Review 1.  Self-regulation and cross-regulation of pattern-recognition receptor signalling in health and disease.

Authors:  Xuetao Cao
Journal:  Nat Rev Immunol       Date:  2016-01       Impact factor: 53.106

2.  Functional polymorphisms of TLR8 are associated with hepatitis C virus infection.

Authors:  Chiou-Huey Wang; Hock-Liew Eng; Kuei-Hsiang Lin; Hsiang-Chun Liu; Cheng-Hsien Chang; Tsun-Mei Lin
Journal:  Immunology       Date:  2014-04       Impact factor: 7.397

3.  Associations between MTHFR Ala222Val polymorphism and risks of hepatitis and hepatitis-related liver cancer: a meta-analysis.

Authors:  Ruiying Zheng; Wenyuan Zhao; Dongwei Dai; Chengzhong Li
Journal:  Tumour Biol       Date:  2013-10-24

Review 4.  Role of innate immunity in the development of hepatocellular carcinoma.

Authors:  Rajagopal N Aravalli
Journal:  World J Gastroenterol       Date:  2013-11-21       Impact factor: 5.742

Review 5.  Regulation of microRNA by hepatitis B virus infection and their possible association with control of innate immunity.

Authors:  Xia Jiang; Tatsuo Kanda; Shuang Wu; Masato Nakamura; Tatsuo Miyamura; Shingo Nakamoto; Arup Banerjee; Osamu Yokosuka
Journal:  World J Gastroenterol       Date:  2014-06-21       Impact factor: 5.742

6.  Glances in Immunology of HIV and HCV Infection.

Authors:  Maria Giovanna Quaranta; Benedetta Mattioli; Stefano Vella
Journal:  Adv Virol       Date:  2012-06-07

Review 7.  The immunopathogenetic role of autoantibodies in canine autoimmune hepatitis: lessons to learn from human autoimmune hepatitis.

Authors:  Christos Liaskos; Athanasios Mavropoulos; Timoklia Orfanidou; Vassiliki Spyrou; Labrini V Athanasiou; Charalambos Billinis
Journal:  Auto Immun Highlights       Date:  2012-10-09

8.  Interaction of TLR-IFN and HLA polymorphisms on susceptibility of chronic HBV infection in Southwest Han Chinese.

Authors:  Dengming He; Shiqi Tao; Shimin Guo; Maoshi Li; Junqiu Wu; Hongfei Huang; Xinwu Guo; Guohua Yan; Peng Zhu; Yuming Wang
Journal:  Liver Int       Date:  2015-01-21       Impact factor: 5.828

9.  Single nucleotide polymorphisms of toll-like receptor 7 and toll-like receptor 9 in hepatitis C virus infection patients from central China.

Authors:  Xin-su Wei; Chuan-dong Wei; Yong-qing Tong; Cheng-liang Zhu; Ping-an Zhang
Journal:  Yonsei Med J       Date:  2014-03       Impact factor: 2.759

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.